Clinical Trial Update: Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Laflavon for lowering triglycerides and increasing HDL; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• Laflavon

Snippet

Sponsor: Omicron Pharmaceuticals | Conditions: Metabolic Disease | Phase 3 | Status: UNKNOWN